198 related articles for article (PubMed ID: 32814843)
1. Long-term outcomes of two ablation techniques for treatment of radio-recurrent prostate cancer.
Nair SM; Peters M; Kurver P; Lavi A; Verhoeff JJC; van der Voort van Zyp JRN; van Son MJ; Chin JL
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):186-192. PubMed ID: 32814843
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Outcomes of Whole Gland Salvage Cryotherapy for Locally Recurrent Prostate Cancer following Radiation Therapy: A Combined Analysis of Two Centers.
Chin JL; Lavi A; Metcalfe MJ; Siddiqui K; Dewar M; Petros FG; Li R; Nogueras González GM; Wang X; Nair SM; Ward JF; Pisters L
J Urol; 2021 Sep; 206(3):646-654. PubMed ID: 33908799
[TBL] [Abstract][Full Text] [Related]
3. Early Versus Delayed Initiation of Salvage Androgen Deprivation Therapy and Risk of Prostate Cancer-Specific Mortality.
Mahal BA; Chen MH; Renshaw AA; Loffredo MJ; Kantoff PW; D'Amico AV
J Natl Compr Canc Netw; 2018 Jun; 16(6):727-734. PubMed ID: 29891524
[No Abstract] [Full Text] [Related]
4. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
[TBL] [Abstract][Full Text] [Related]
5. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
6. Combination of Androgen Deprivation Therapy and Salvage Radiotherapy versus Salvage Radiotherapy Alone for Recurrent Prostate Cancer after Radical Prostatectomy.
Yoo S; You D; Kim YS; Hong JH; Ahn H; Kim CS
Urol Int; 2017; 99(4):406-413. PubMed ID: 29020683
[TBL] [Abstract][Full Text] [Related]
7. High-intensity Focused Ultrasound (HIFU) as salvage therapy for radio-recurrent prostate cancer: predictors of disease response.
Dason S; Wong NC; Allard CB; Hoogenes J; Orovan W; Shayegan B
Int Braz J Urol; 2018; 44(2):248-257. PubMed ID: 29211405
[TBL] [Abstract][Full Text] [Related]
8. Natural history of 'second' biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study.
Tumati V; Jackson WC; Abugharib AE; Raj G; Roehrborn C; Lotan Y; Courtney K; Bagrodia A; Gahan JC; Zumsteg ZS; Folkert MR; Laine AM; Hannan R; Spratt DE; Desai NB
BJU Int; 2018 Mar; 121(3):365-372. PubMed ID: 28581200
[TBL] [Abstract][Full Text] [Related]
9. Type of patients in whom biochemical recurrence after radical prostatectomy can be observed without salvage therapy.
Matsumoto K; Niwa N; Hagiwara M; Kosaka T; Tanaka N; Takeda T; Morita S; Mizuno R; Shinojima T; Hara S; Asanuma H; Oya M
World J Urol; 2020 Jul; 38(7):1749-1756. PubMed ID: 31559475
[TBL] [Abstract][Full Text] [Related]
10. Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.
Naik M; Reddy CA; Stephans KL; Ciezki JP; Garcia J; Grivas P; Stephenson AJ; Klein EA; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):617-23. PubMed ID: 27681757
[TBL] [Abstract][Full Text] [Related]
11. The impact of timing of salvage hormonal therapy on survival after brachytherapy for prostate cancer.
Sagalovich D; Leapman M; Sfakianos J; Hall S; Stock R; Stone N
Brachytherapy; 2016; 15(6):730-735. PubMed ID: 27743956
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up comparing salvage radiation therapy and androgen-deprivation therapy for biochemical recurrence after radical prostatectomy.
Matsumoto K; Niwa N; Hagiwara M; Kosaka T; Takeda T; Yasumizu Y; Tanaka N; Morita S; Mizuno R; Shinojima T; Hara S; Asanuma H; Oya M
Int J Clin Oncol; 2021 Apr; 26(4):744-752. PubMed ID: 33387085
[TBL] [Abstract][Full Text] [Related]
13. Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure.
Jackson WC; Suresh K; Tumati V; Dess RT; Soni PD; Zhao SG; Zumsteg ZS; Hannan R; Hollenbeck BK; George A; Kaffenberger SD; Salami SS; Hearn JWD; Morgan TM; Mehra R; Schipper M; Feng FY; Desai NB; Spratt DE
Eur Urol Oncol; 2018 Sep; 1(4):276-282. PubMed ID: 31100248
[TBL] [Abstract][Full Text] [Related]
14. High PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy?
Mahal BA; Chen MH; Bennett CL; Kattan MW; Sartor O; Stein K; D'Amico AV; Nguyen PL
Ann Oncol; 2015 Jul; 26(7):1390-5. PubMed ID: 25926039
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of intensity-modulated radiation therapy combined with neoadjuvant androgen deprivation therapy under an early salvage policy for patients with T3-T4N0M0 prostate cancer.
Mizowaki T; Norihisa Y; Takayama K; Ikeda I; Inokuchi H; Nakamura K; Kamba T; Inoue T; Kamoto T; Ogawa O; Hiraoka M
Int J Clin Oncol; 2016 Feb; 21(1):148-55. PubMed ID: 26141133
[TBL] [Abstract][Full Text] [Related]
16. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
17. Strategy for PSA progression in patients undergoing salvage radiation for biochemical recurrence after radical prostatectomy.
Saito T; Matsumoto K; Kosaka T; Yasumizu Y; Tanaka N; Takeda T; Morita S; Mizuno R; Asanuma H; Oya M
Int J Clin Oncol; 2023 May; 28(5):707-715. PubMed ID: 36929093
[TBL] [Abstract][Full Text] [Related]
18. Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
Eur Urol; 2014 Mar; 65(3):620-7. PubMed ID: 23245686
[TBL] [Abstract][Full Text] [Related]
19. Predictors of biochemical failure in patients undergoing prostate whole-gland salvage cryotherapy: a novel risk stratification model.
Spiess PE; Levy DA; Mouraviev V; Pisters LL; Jones JS
BJU Int; 2013 Aug; 112(4):E256-61. PubMed ID: 23469778
[TBL] [Abstract][Full Text] [Related]
20. Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy.
Ghadjar P; Aebersold DM; Albrecht C; Böhmer D; Flentje M; Ganswindt U; Höcht S; Hölscher T; Sedlmayer F; Wenz F; Zips D; Wiegel T;
Strahlenther Onkol; 2018 Jul; 194(7):619-626. PubMed ID: 29383406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]